Instrumentation Laboratory Unveils New Corporate Brand
-- Part of New Corporate Rebranding of Parent Company, Werfen --
BEDFORD, Mass., July 29, 2014 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the launch of its new corporate brand identity, including a new corporate logo. This is part of a comprehensive rebranding effort by Werfen, the parent company of IL.
Founded in Boston, MA, in 1959, IL has been part of the Werfen Group family of companies since 1992. Other companies in the group include Inova Diagnostics (San Diego, CA), Biokit and Systelab (Barcelona, Spain). Like IL, these three companies are focused on In Vitro Diagnostics (IVD). As part of the corporate rebranding process, "Werfen Group" will now be known simply as "Werfen."
Werfen has helped to instill and cement what collectively defines IL and the other companies in the group today: Passion, Integrity, Customer-Focus and Innovation. They will continue to be instrumental in supporting the growth of IL and its investments in research and development, new products and services.
The new logo of each Werfen company, including IL, incorporates a "W" icon, signifying "Werfen" as its central graphic element. Additionally, the name of each company is conveyed in a unified typefont. Thus, the new brand identities better reflect the links and synergies among each company and their relationship to Werfen and each other.
"Our new brand identity is about more than just a change to our logos. It is about IL renewing our commitment to innovation, in close partnership with Werfen and our sister companies. By aligning and working closely together, we optimize the very best science and technology each company has to offer and capitalize on our collective wisdom and expertise," said Ramon Benet, CEO at IL. "Ultimately, this allows us to deliver the highest quality IVD products for the very best patient care."
IL now will begin to incorporate their new brand identity into their products, packaging, software, and communication vehicles. During a transition period, a mix of the old and new logos will be in the market. Full implementation may require several years to complete. Regardless of which IL logo appears on a product, IL and its commitment to quality remain unchanged.
The legal name for IL and any contracts or purchasing agreements with IL are unaffected. Products, Service and Support, along with all contact information, will remain the same.
Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL's GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers. IL's Hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, comprised of the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, ACL TOP 500 CTS and ACL TOP 300 CTS. IL also offers the ACL AcuStar®, ACL ELITE®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents. IL is based in Bedford, Massachusetts.
The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
SOURCE Instrumentation Laboratory
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article